Medical platformer M3 (TSE:2413, Financial) was also a major contributor to the performance with its Japan platform now covering 90% of all doctors. The company is utilizing the platform to expand and disrupt the areas of contract research organizations and career business recruitment and networking, in Japan and other markets. Overseas is a meaningful part of overall revenue, with China being the largest growth driver.
From the Matthews Japan Fund (Trades, Portfolio)'s fourth-quarter 2020 commentary.
